Table 2.

ERG-positive and ERG-negative incident prostate cancer by aspirin use (fully adjusted modela)

No. of casesHR (95% CI)
ERG-positiveERG-negative
Total439473ERG-positiveERG-negative
Categories of use
 Never user1471381 (ref)1 (ref)
 Past user1071141.02 (0.79–1.31)1.04 (0.82–1.33)
 Current user1852211.03 (0.83–1.28)1.11 (0.89–1.37)
Pheterogeneity = 0.88
Current use
 Never/past user2542521 (ref)1 (ref)
 Current user1852211.02 (0.85–1.23)1.09 (0.91–1.30)
Pheterogeneity = 0.63
Ever use
 Never user1471381 (ref)1 (ref)
 Ever user2923351.03 (0.84–1.25)1.08 (0.89–1.33)
Pheterogeneity = 0.69
Duration of use since baseline
 Non-aspirin user1471381 (ref)1 (ref)
 Aspirin use <5 years1341491.00 (0.79–1.26)1.17 (0.94–1.46)
 Aspirin use 5–<10 years90921.11 (0.85–1.44)0.98 (0.76–1.28)
 Aspirin use 10 years+68940.96 (0.71–1.30)1.03 (0.77–1.37)
Pheterogeneity = 0.48
 Per year of use4394731.00 (1.00–1.00)1.00 (1.00–1.00)
Pheterogeneity = 0.62
Frequency of use
 Aspirin use <2 d/wk (never/past user)2542521 (ref)1 (ref)
 Aspirin use 2–<6 d/wk72810.94 (0.73–1.21)1.05 (0.83–1.33)
 Aspirin use 6+ d/wk1131401.09 (0.87–1.37)1.12 (0.90–1.39)
Pheterogeneity = 0.82
 Per d/wk of use4394731.02 (0.98–1.05)1.01 (0.98–1.05)
Pheterogeneity = 0.93
  • Abbreviation: ref, reference category.

  • aAdjusted for age, calendar time, race (Caucasian, other), family history of prostate cancer in father or brother (yes, no), height (≤68, >68–70, >70–72, >72 inches), body mass index (<21, 21–<25, 25–<30, 30+ kg/m2), body mass index at age 21 years (<20, 21–<25, 25–<30, 30+ kg/m2), physical activity (quintiles of metabolic equivalents-hours/week), smoking (never, former/quit >10 years ago, former/quit ≤10 years ago, current), history of diabetes (yes, no), time-varying current statin use (yes, no), PSA testing in the 2 years prior to the questionnaire date (yes, no; lagged by one period to avoid counting diagnostic PSA tests as screening), and PSA testing in >50% of possible time periods (yes, no; lagged by one period to avoid counting diagnostic PSA tests as screening).